Inhibition of STAT3 by Napabucasin, a Phase II/III FDA-approved drug, significantly abrogated the capacity of DDR1-expressing cancer cells to form lung metastases from bladder cancer (Lee et al, 2019). Here, STAT3 is linked to urinary bladder cancer.